PALO ALTO, Calif.--Michael Steinmetz, managing director of the biotechnology venture capital firm Venture Asset Management, Cambridge, Mass., was elected to the board of directors of the bioinformation technology company Caliper Technologies here. Steinmetz also serves as acting CEO of the new, Munich-based, functional genomics company Genome Pharmaceuticals, and was previously vice-president of preclinical R&D for Hoffmann-LaRoche.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.